Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, Genvoya contains tenofovir alafenamide and emtricitabine and should not be administered with tenofovir-DF or additional emtricitabine (both components of Truvada).
Genvoya should not be co-administered with other antiretroviral medicinal products. Genvoya should not be administered concomitantly with medicinal products containing tenofovir disoproxil.
Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.
Genvoya is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration of Genvoya with other antiretroviral medications for treatment of HIV-1 infection should be avoided.
Genvoya Prescribing Information, Gilead Sciences Inc, September 2021.
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir alafenamide.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking